Sonny T. Lisal, Hawaidah Hawaidah, Dessy Natalia, A. Seweng, Yuyun Widaningsih, Erlyn Limoa, S. Syamsuddin
{"title":"利培酮对已确诊的 COVID-19 精神分裂症患者的 PANSS 评分和 IL-6 的疗效","authors":"Sonny T. Lisal, Hawaidah Hawaidah, Dessy Natalia, A. Seweng, Yuyun Widaningsih, Erlyn Limoa, S. Syamsuddin","doi":"10.4081/hls.2024.12723","DOIUrl":null,"url":null,"abstract":"The study aimed to determine the efficacy of risperidone on PANSS scores and Interleukin 6 (IL-6) levels in schizophrenia patients with confirmed COVID-19. The study type was analytical observational, with a prospective cohort design. The subjects included inpatient Schizophrenia patients with and without COVID-19, mild-moderate and asymptomatic COVID-19, and schizophrenic patients without COVID-19 who were hospitalized and met the inclusion and exclusion criteria, for a total of 22 subjects in each group. The Positive and Negative Syndrome Scale (PANSS) and Elisa Interleukin 6 (IL-6) serum were sampled consecutively for this study. In the positive covid-19 group, the Mean IL-6 Post was significantly lower than Pre (23.0 vs. 26.1, p<0.001), while in the control group, the Mean IL-6 Post (four weeks) was significantly lower than Pre (baseline), with 19.3 vs. 21.0 (p<0.001). Serum IL-6 levels appeared to be an effective prognostic biomarker in COVID-19 patients. The 35 pg/mL cut-off point could distinguish mild-moderate patients from more severe ones. We discovered that schizophrenia patients with verified positive COVID-19 received COVID-19 therapy in the form of a combination of antipsychotic and antivirals had IL-6 levels lower than 35 pg/mL, indicating the role of antipsychotic (risperidone) and antiviral in reducing IL-6 levels.","PeriodicalId":507714,"journal":{"name":"Healthcare in Low-resource Settings","volume":"36 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effectiveness of risperidone on PANSS score and IL-6 in confirmed COVID-19 schizophrenic patients\",\"authors\":\"Sonny T. Lisal, Hawaidah Hawaidah, Dessy Natalia, A. Seweng, Yuyun Widaningsih, Erlyn Limoa, S. Syamsuddin\",\"doi\":\"10.4081/hls.2024.12723\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The study aimed to determine the efficacy of risperidone on PANSS scores and Interleukin 6 (IL-6) levels in schizophrenia patients with confirmed COVID-19. The study type was analytical observational, with a prospective cohort design. The subjects included inpatient Schizophrenia patients with and without COVID-19, mild-moderate and asymptomatic COVID-19, and schizophrenic patients without COVID-19 who were hospitalized and met the inclusion and exclusion criteria, for a total of 22 subjects in each group. The Positive and Negative Syndrome Scale (PANSS) and Elisa Interleukin 6 (IL-6) serum were sampled consecutively for this study. In the positive covid-19 group, the Mean IL-6 Post was significantly lower than Pre (23.0 vs. 26.1, p<0.001), while in the control group, the Mean IL-6 Post (four weeks) was significantly lower than Pre (baseline), with 19.3 vs. 21.0 (p<0.001). Serum IL-6 levels appeared to be an effective prognostic biomarker in COVID-19 patients. The 35 pg/mL cut-off point could distinguish mild-moderate patients from more severe ones. We discovered that schizophrenia patients with verified positive COVID-19 received COVID-19 therapy in the form of a combination of antipsychotic and antivirals had IL-6 levels lower than 35 pg/mL, indicating the role of antipsychotic (risperidone) and antiviral in reducing IL-6 levels.\",\"PeriodicalId\":507714,\"journal\":{\"name\":\"Healthcare in Low-resource Settings\",\"volume\":\"36 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Healthcare in Low-resource Settings\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/hls.2024.12723\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare in Low-resource Settings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/hls.2024.12723","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The effectiveness of risperidone on PANSS score and IL-6 in confirmed COVID-19 schizophrenic patients
The study aimed to determine the efficacy of risperidone on PANSS scores and Interleukin 6 (IL-6) levels in schizophrenia patients with confirmed COVID-19. The study type was analytical observational, with a prospective cohort design. The subjects included inpatient Schizophrenia patients with and without COVID-19, mild-moderate and asymptomatic COVID-19, and schizophrenic patients without COVID-19 who were hospitalized and met the inclusion and exclusion criteria, for a total of 22 subjects in each group. The Positive and Negative Syndrome Scale (PANSS) and Elisa Interleukin 6 (IL-6) serum were sampled consecutively for this study. In the positive covid-19 group, the Mean IL-6 Post was significantly lower than Pre (23.0 vs. 26.1, p<0.001), while in the control group, the Mean IL-6 Post (four weeks) was significantly lower than Pre (baseline), with 19.3 vs. 21.0 (p<0.001). Serum IL-6 levels appeared to be an effective prognostic biomarker in COVID-19 patients. The 35 pg/mL cut-off point could distinguish mild-moderate patients from more severe ones. We discovered that schizophrenia patients with verified positive COVID-19 received COVID-19 therapy in the form of a combination of antipsychotic and antivirals had IL-6 levels lower than 35 pg/mL, indicating the role of antipsychotic (risperidone) and antiviral in reducing IL-6 levels.